Superworth

Neogenomics price to free cash flow NEO

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
162×
Feb 2020
10-year median
85.4×
10-year range
34.8× to 393×
Peer median
11.5×

Neogenomics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2020, at 162×.

On the days it had one over the last ten years, its median was 85.4×, from 34.8× in Mar 2017 to 393× in Sep 2017.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2020162×162×195×
2019170×56.9×203×
201855.1×46.9×190×
2017303×34.8×393×
201637.4×37.4×168×
2015188×48.9×196×
201452.8×52.8×239×
2013200×192×210×

Against its peers

Companies in Specialty Business Services nearest Neogenomics' size, closest first, today.

CompanyPrice to free cash flow
NEONeogenomicsn/m
MHMcGraw Hill7.3×
VVXV2X20.0×
DFINDonnelley Financial Solutions9.2×
CRAICRA Internationaln/m
ITGartner11.5×
ULSUL Solutions34.8×
Peer median11.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Neogenomics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.